The drug developer’s chief scientific officer, Dr John Reader, said: "The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets."
() said it has been formally granted a US patent over its SDC-1802 TYK2/JAK1 kinase inhibitor programme, which is in pre-clinical development targeting cancer.
It means the company’s technology is now patented in all major territories, including Europe, Japan and China.
The drug developer’s chief scientific officer, Dr John Reader, said: "The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.
“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company's negotiating position as it continues to engage in discussions with potential licence partners."
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
